Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | PYGB | P11216 | 7/20 | 0.37 |
| ▸ | PYGL | P06737 | 3/20 | 0.37 |
| ▸ | PYGM | P11217 | 2/20 | 0.37 |
| ▸ | CDK1 | P06493 | 1/20 | 0.36 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.36 |
| ▸ | GBA1 | P04062 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19242663 | 1.00 | MEN1 (0.51) | MEN1KMT2APYGBPYGLPYGM | |
| SCHEMBL6376667 | 1.00 | MEN1 (0.51) | MEN1KMT2APYGBPYGLPYGM | |
| SCHEMBL2853265 | 1.00 | MEN1 (0.51) | MEN1KMT2APYGBPYGLPYGM | |
| SCHEMBL8522586 | 1.00 | MEN1 (0.51) | MEN1KMT2APYGBPYGLPYGM | |
| SCHEMBL4969252 | 1.00 | MEN1 (0.51) | MEN1KMT2APYGBPYGLPYGM | |
| SCHEMBL12689155 | 1.00 | MEN1 (0.51) | MEN1KMT2APYGBPYGLPYGM | |
| SCHEMBL15814770 | 1.00 | MEN1 (0.51) | MEN1KMT2APYGBPYGLPYGM | |
| SCHEMBL9006 | 1.00 | MEN1 (0.51) | MEN1KMT2APYGBPYGLPYGM | |
| SCHEMBL10013929 | 1.00 | MEN1 (0.51) | MEN1KMT2APYGBPYGLPYGM | |
| SCHEMBL15959591 | 1.00 | MEN1 (0.51) | MEN1KMT2APYGBPYGLPYGM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10588962-B2 | Carbohydrate-glycolipid conjugate vaccines | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2020-03-17 | — | — | US | claimed |
| US-20150238597-A1 | CARBOHYDRATE-GLYCOLIPID CONJUGATE VACCINES | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-08-27 | — | — | US | claimed |
| US-20150216985-A1 | ENDOSPORE COMPOSITIONS AND USES THEREOF | Annuary Healthcare Inc. | 2015-08-06 | — | — | US | claimed |
| EP-2827899-B1 | POLYSACCHARIDE ANTIGEN-GLYCOLIPID CONJUGATE VACCINES | MAX PLANCK GES ZUR FÖRDERUNG DER WISSENSCHAFTEN E V (DE) | 2015-08-05 | — | — | EP | claimed |
| EP-2827899-A1 | CARBOHYDRATE-GLYCOLIPID CONJUGATE VACCINES | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-01-28 | — | — | EP | claimed |
| WO-2013178236-A1 | CARBOHYDRATE-GLYCOLIPID CONJUGATE VACCINES | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V. (DE) | 2013-12-05 | — | — | WO | claimed |
| WO-2013139803-A1 | CARBOHYDRATE-GLYCOLIPID CONJUGATE VACCINES | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2013-09-26 | — | — | WO | claimed |
| EP-1902063-A2 | DERIVATIVES OF PENTOSE MONOSACCHARIDES AS ANTI-INFLAMMATORY COMPOUNDS | Ranbaxy Laboratories Limited (IN) | 2008-03-26 | — | — | EP | claimed |
| WO-2007063356-A2 | DERIVATIVES OF PENTOSE MONOSACCHARIDES AS ANTI-INFLAMMATORY COMPOUNDS | RANBAXY LABORATORIES LIMITED (IN) | 2007-06-07 | — | — | WO | claimed |
| US-20260062633-A1 | EMULSION | QUADRISE INTERNATIONAL LTD (GB) | 2026-03-05 | — | — | US | disclosed |
| US-12453960-B1 | Nanocomposite material fabrication | IMAM MOHAMMAD IBN SAUD ISLAMIC UNIVERISTY (SA) | 2025-10-28 | — | — | US | disclosed |
| EP-4581107-A1 | EMULSION | Quadrise International Ltd (GB) | 2025-07-09 | — | — | EP | disclosed |
| US-20240124911-A1 | ENZYMATIC METHOD FOR PREPARATION OF GDP-FUCOSE | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2024-04-18 | — | — | US | disclosed |
| WO-2024047354-A1 | EMULSION | QUADRISE INTERNATIONAL LIMITED (GB) | 2024-03-07 | — | — | WO | disclosed |
| US-4460767-A | COPPER COMPOUND, CHLORIDE OR BROMIDE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1984-07-17 | — | — | US | disclosed |
| US-4337080-A | DERIVATIVE OF 2,3:4,6-DI-O-ISOPROPYLIDENE-2-KETOGULONIC ACID | HOFFMANN-LA ROCHE INC. (US) | 1982-06-29 | — | — | US | disclosed |
| US-4067722-A | COPPER(II) COMPLEXES OF 2,3:4,6-DI-O-(SUBSTITUTED)-ALPHA-L-XYLO-2-HEXULOFURANOSONIC ACID | HOFFMANN-LA ROCHE INC. (US) | 1978-01-10 | — | — | US | disclosed |
| US-4061489-A | GLUCONIC ACID DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 1977-12-06 | — | — | US | disclosed |
| US-4007206-A | HERBICIDE, PLANT GROWTH REGULATOR | HOFFMANN-LA ROCHE INC. (US) | 1977-02-08 | — | — | US | disclosed |
| US-3931149-A | PLANT GROWTH REGULATORS | HOFFMANN-LA ROCHE INC. (US) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062633-A1 | EMULSION | C5, PHOSPHO1, PFKFB1 | MEN1 3528/4885KMT2A 3776/4885PYGB 1180/4885 |
| US-20150216985-A1 | ENDOSPORE COMPOSITIONS AND USES THEREOF | CUTA, SUCLG1, CD47 | MEN1 2446/4885KMT2A 3655/4885PYGB 408/4885 |
| US-20150238597-A1 | CARBOHYDRATE-GLYCOLIPID CONJUGATE VACCINES | STT3B, STT3A, DDOST | MEN1 2616/4885KMT2A 2780/4885PYGB 553/4885 |
| US-10588962-B2 | Carbohydrate-glycolipid conjugate vaccines | STT3B, STT3A, DDOST | MEN1 2616/4885KMT2A 2780/4885PYGB 553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.